首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1735608

破傷風類毒素疫苗市場（2026-2032）：依疫苗類型、年齡層、最終用戶和地區分類

Tetanus Toxoid Vaccine Market By Vaccine Type, By Age Group, By End-User, And Region for 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

破傷風類毒素疫苗市場評估-2026-2032

破傷風類毒素疫苗市場的主要驅動力在於全球人們對預防性醫療保健措施的認知不斷提高，以及破傷風感染率的上升。根據 Verified Market Research 分析師預測，破傷風類毒素疫苗市場規模預計將從 2024 年的 51 億美元下降至 2032 年預測期內的 80.4 億美元。

政府改善免疫系統的舉措以及將破傷風疫苗納入常規免疫計劃正在推動市場擴張，這將有助於市場在 2026 年至 2032 年期間以 5.85% 的複合年成長率成長。

破傷風類毒素疫苗市場定義/概述

破傷風類毒素疫苗用於預防破傷風。破傷風是一種由破傷風梭菌引起的嚴重細菌感染疾病。此疫苗可刺激免疫系統產生針對破傷風毒素的抗體，進而增強對未來感染的免疫力。破傷風類毒素疫苗主要透過注射給藥，通常包含在兒童常規疫苗接種計畫中。

此外，也會進行加強疫苗接種，以維持終身免疫。這種疫苗對於預防破傷風至關重要。破傷風是一種由受污染的傷口或損傷引起的疾病，其特徵是嚴重的肌肉痙攣，有時甚至可能致命。

推動破傷風類毒素疫苗需求的關鍵因素有哪些？

破傷風仍然是全球許多地區面臨的健康問題，尤其是在疫苗接種覆蓋率低且易機會破傷風梭菌（例如透過農業勞動或衛生條件不佳）的地區。隨著破傷風在世界各地反覆出現，對破傷風類毒素疫苗的需求日益成長。

各國政府以及世界衛生組織（WHO）、聯合國兒童基金會等國際衛生組織積極推廣破傷風疫苗接種，將其作為標準免疫方案和孕產婦及新生兒破傷風消除活動的一部分。這些舉措旨在實現孕婦和兒童等特定族群的高覆蓋率，從而顯著增加對破傷風類毒素疫苗的需求。

此外，疫苗技術和生產流程的進步促進了破傷風類毒素疫苗的研發，使其更有效、更安全且易於接種。能夠預防多種疾病（包括破傷風）的聯合疫苗因其簡單有效而日益受到歡迎。此類創新有望提高免疫接種計劃的有效性，並透過增強其對醫護人員和患者的吸引力來擴大市場。

哪些挑戰阻礙了破傷風類毒素疫苗的發展？

由於物流方面的挑戰，包括儲存設施差、低溫運輸要求高和配送網路不完善，許多中低收入國家破傷風疫苗的取得管道有限。這些問題在農村和偏遠地區尤其嚴重，因為這些地區的醫療基礎設施通常較差。確保最需要疫苗的地方能夠獲得疫苗，是破傷風預防公共衛生工作的一大挑戰，限制了市場擴張。

此外，破傷風類毒素疫苗的生產、分發和管理需要大量投資，許多國家，特別是醫療預算較少的國家，難以獲得足夠的資金來維持和擴大其免疫計畫。

當經濟不穩定或資金籌措重點改變時，疫苗覆蓋率也會下降。國際援助和資金籌措方式固然重要，但取決於全球衛生目標和經濟狀況。

The Tetanus Toxoid Vaccine Market is primarily driven by increased awareness of preventative healthcare measures, as well as rising tetanus infection rates worldwide. According to the analyst from Verified Market Research, the Tetanus Toxoid Vaccine Market is estimated to reach a valuation of USD 8.04 Billion over the forecast period 2032, subjugating around USD 5.1 Billion in 2024.

Government measures to improve immunization systems, as well as the incorporation of tetanus vaccination into normal immunization schedules, are driving market expansion. This enables the market to grow at a CAGR of 5.85% from 2026-2032.

Tetanus Toxoid Vaccine Market: Definition/ Overview

Tetanus toxoid vaccine is a medicinal treatment that prevents tetanus, a severe bacterial infection caused by Clostridium tetani. This vaccination stimulates the immune system to develop antibodies against the tetanus toxin, providing immunity against future infections. Tetanus toxoid vaccinations are primarily administered by injection and are frequently included in normal children's immunization schedules.

Furthermore, people receive booster doses to maintain immunity throughout their lives. The vaccination is critical for preventing tetanus, a disease characterized by severe muscle spasms and possibly fatal consequences caused by contaminated wounds or injuries.

What are the Key Drivers that Foster the Demand for Tetanus Toxoid Vaccines?

Tetanus is a health concern in many parts of the world, particularly in regions with low vaccination coverage and people who are more exposed to the bacteria Clostridium tetani (for example, through agricultural work or inadequate sanitation). The continual recurrence of tetanus cases around the world pushes up demand for tetanus toxoid vaccinations, which are the principal way of disease prevention.

Governments and international health organizations, such as the World Health Organization (WHO) and UNICEF, aggressively encourage tetanus immunization as part of standard vaccination regimens and maternal and neonatal tetanus elimination initiatives. These initiatives considerably raise demand for tetanus toxoid vaccinations since they aim to attain high vaccination rates in specific populations such as pregnant women and children.

Furthermore, advances in vaccine technology and production techniques have resulted in the creation of tetanus toxoid vaccines that are more effective, safer, and easier to administer. Combination vaccines that protect against numerous illnesses, including tetanus, are becoming more popular due to their simplicity and efficacy. Such innovations have the potential to extend the market by improving immunization programs' effectiveness and appeal to both healthcare professionals and recipients.

What are the Challenges Hindering the Growth of the Tetanus Toxoid Vaccines?

Many low- and middle-income nations have limited access to tetanus vaccines because of logistical challenges such as poor storage facilities, cold chain requirements, and distribution networks. These problems are exacerbated in rural or isolated places, where healthcare infrastructure is frequently poor. Ensuring that vaccines are available where they are most needed is a big challenge for public health efforts to prevent tetanus, limiting market expansion.

Furthermore, tetanus toxoid vaccines require significant investment to manufacture, distribute, and administer. Many countries, particularly those with low healthcare budgets, struggle to provide enough cash to maintain or grow immunization programs.

Also, economic instability or shifts in financing priorities lead to a decrease in immunization coverage. International aid and financing methods are important, but they are influenced by global health goals and economic situations.

Category-Wise Acumens

What Factors Contribute to the Market Growth of Diphtheria, Tetanus, and Pertussis Vaccines?

According to VMR analysis, the diphtheria, tetanus, and pertussis (DTaP) segment is estimated to exhibit the highest growth during the forecast period. DTaP vaccines are a cornerstone of pediatric immunization programs around the world because they effectively protect against three deadly diseases: diphtheria, tetanus, and pertussis. Many nations incorporate DTaP into their national immunization schedules for children, advising multiple doses to provide long-term immunity. This widespread and habitual use creates a strong demand for vaccines.

The global increase in pertussis (whooping cough) infections has highlighted the need for immunization. The DTaP vaccination protects against pertussis in addition to tetanus and diphtheria, making it particularly useful in attempts to control outbreaks and preserve public health. The rise in pertussis infections, particularly in nations with previously low incidence rates, has raised attention on immunization, driving up demand for DTaP vaccines.

Furthermore, the recommendation for pregnant women to obtain the Tdap vaccine (a variation of DTaP for adolescents and adults) to protect their newborns from pertussis before they reach the age to be vaccinated has also contributed to the segment's dominance. This method, known as "cocooning," seeks to surround infants with family members who have been vaccinated against pertussis, lowering the infant's chance of infection. While Tdap is a related but distinct formulation targeted for older children and adults, its usage supplements the larger strategy of employing DTaP in childhood immunization, strengthening the overall demand for vaccines that protect against tetanus, diphtheria, and pertussis.

What are the Key Driving Forces Leading to the Dominance of the Pediatric Age Group?

The pediatric segment is estimated to dominate the Tetanus Toxoid Vaccine Market during the forecast period. Tetanus vaccines are included in the children's immunization schedule all around the world. Children should get numerous doses of the vaccine (typically coupled with diphtheria and pertussis vaccines as DTP/DTaP) beginning in infancy to develop and maintain immunity. This regular inclusion in national immunization programs maintains a steady demand for the vaccine among the pediatric population.

International and national health organizations promote high vaccination rates among youngsters to prevent epidemics of vaccine-preventable illnesses such as tetanus. The emphasis on children stems from their increased susceptibility to infectious diseases and the long-term benefits of early immunization. Efforts to obtain and maintain high coverage rates in this segment have a substantial impact on the pediatric segment's market dominance.

Furthermore, many countries demand proof of immunization, including tetanus toxoid, for school enrollment. This regulatory strategy ensures that the vast majority of the pediatric population is immunized, which contributes to the segment's significant market share. Such initiatives not only benefit public health but also create ongoing demand for pediatric immunizations.

Country/Region-wise Acumens

What Drivers Contribute to the Sustained Dominance of North America in this Market?

According to VMR analyst, North America is estimated to dominate the Tetanus Toxoid Vaccine Market during the forecast period. North America, particularly the United States and Canada, benefits from a strong healthcare system. This includes easy access to healthcare services, a robust network of hospitals and clinics, and comprehensive immunization programs. Such infrastructure enables efficient vaccine distribution and administration, resulting in high immunization coverage rates. The region's cold chain storage and distribution capabilities are also crucial to ensuring vaccine efficacy from production to administration.

Furthermore, both the United States and Canada devote large money to public health initiatives, including immunization programs. These contributions support not only vaccine purchases but also public health programs aimed at increasing vaccination knowledge and uptake, particularly tetanus toxoid vaccines. Government and commercial insurance coverage for vaccinations helps to increase immunization rates by lowering people's out-of-pocket costs.

What are the Factors Leading to Significant Share in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. Many Asia Pacific countries are experiencing strong economic expansion, which has resulted in greater healthcare spending and major infrastructure upgrades. Governments are investing more in healthcare facilities, vaccine procurement, and cold chain logistics, boosting the region's ability to carry out widespread immunization programs. This finding promotes increased immunization rates and increases demand for tetanus toxoid vaccines.

Furthermore, the Asia Pacific region is home to some of the world's most populated countries, including China and India. With a huge number of newborns and children requiring vaccination as part of standard immunization schedules, there is a high demand for tetanus toxoid vaccines. Furthermore, attempts to enhance maternal health lead to increased immunization among women of reproductive age, which expands the market.

Competitive Landscape

The competitive landscape of the Tetanus Toxoid Vaccine Market is distinguished by the presence of multiple firms working to improve vaccine accessibility, efficacy, and safety. Also, advances in vaccination technology, such as the creation of new adjuvants or combination vaccines, help to increase competition by providing differentiated products.

Some of the prominent players operating in the Tetanus Toxoid Vaccine Market include:

GlaxoSmithKline, Sanofi Pasteur, Merck & Co., Serum Institute of India, Bharat Biotech International Limited, Walvax Biotechnology Co., Wuhan Institute of Biological Products Co., China National Biotec Group Co., Evans Vaccines, Biological E. Limited, CanSino Biologics Inc., Abbott Laboratories, Hoffmann-La Roche Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, AstraZeneca plc, CSL Limited, Mylan N.V., Novartis International AG

Latest Developments

In March 2024, Sanofi Pasteur established a collaboration with UNICEF to enhance childhood immunization access in Africa.
In March 2024, Pfizer Inc. published encouraging results from a late-stage clinical trial for a novel respiratory syncytial virus (RSV) vaccine.
In February 2024, The Serum Institute of India reported great financial performance due to increased demand for several vaccines, notably tetanus toxoid vaccines.

1 INTRODUCTION OF GLOBAL TETANUS TOXOID VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL TETANUS TOXOID VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL TETANUS TOXOID VACCINE MARKET, BY VACCINE TYPE

5.1 Overview
5.2 Tetanus Toxoid (TT)
5.3 Diphtheria and Tetanus (DT)
5.4 Tetanus and Diphtheria (Td)
5.5 Diphtheria, Tetanus, and Pertussis (DTaP)
5.6 Tetanus, Diphtheria, and Pertussis (Tdap)
5.7 Pentavalent
5.8 Hexavalent
5.9 Others

6 GLOBAL TETANUS TOXOID VACCINE MARKET, BY AGE GROUP

6.1 Overview
6.2 Pediatric
6.3 Adult

7 GLOBAL TETANUS TOXOID VACCINE MARKET, BY END-USER

7.1 Overview
7.2 Hospitals and Clinics
7.3 Government Organizations
7.4 Others

8 GLOBAL TETANUS TOXOID VACCINE MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Middle East and Africa
- 8.5.2 Latin America

9 GLOBAL TETANUS TOXOID VACCINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 GlaxoSmithKline
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Sanofi Pasteur
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Merck & Co.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Serum Institute of India
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Bharat Biotech International Limited
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Walvax Biotechnology Co.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Wuhan Institute of Biological Products Co.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 China National Biotec Group Co.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Evans Vaccines
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Biological E. Limited
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments